In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors
- 2 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Protein Journal
- Vol. 40 (3), 296-309
- https://doi.org/10.1007/s10930-020-09945-6
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emanating human infectious coronavirus that causes COVID-19 disease. On 11th March 2020, it has been announced as a pandemic by the World Health Organization (WHO). Recently, several repositioned drugs have been subjected to clinical investigations as anti-COVID-19 drugs. Here, in silico drug discovery tools were utilized to evaluate the binding affinities and features of eighteen anti-COVID-19 drug candidates against SARS-CoV-2 main protease (Mpro). Molecular docking calculations using Autodock Vina showed considerable binding affinities of the investigated drugs with docking scores ranging from − 5.3 to − 8.3 kcal/mol, with higher binding affinities for HIV drugs compared to the other antiviral drugs. Molecular dynamics (MD) simulations were performed for the predicted drug-Mpro complexes for 50 ns, followed by binding energy calculations utilizing molecular mechanics-generalized Born surface area (MM-GBSA) approach. MM-GBSA calculations demonstrated promising binding affinities of TMC-310911 and ritonavir towards SARS-CoV-2 Mpro, with binding energy values of − 52.8 and − 49.4 kcal/mol, respectively. Surpass potentialities of TMC-310911 and ritonavir are returned to their capabilities of forming multiple hydrogen bonds with the proximal amino acids inside Mpro's binding site. Structural and energetic analyses involving root-mean-square deviation, binding energy per-frame, center-of-mass distance, and hydrogen bond length demonstrated the stability of TMC-310911 and ritonavir inside the Mpro's active site over the 50 ns MD simulation. This study sheds light on HIV protease drugs as prospective SARS-CoV-2 Mpro inhibitors. Graphic AbstractFunding Information
- Science and Technology Development Fund (5480, 7972)
- King Khalid University (R.G.P 2/90/41)
This publication has 43 references indexed in Scilit:
- DrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Research, 2017
- Molecular docking as a popular tool in drug design, an in silico travelAdvances and Applications in Bioinformatics and Chemistry, 2016
- Computational protein–ligand docking and virtual drug screening with the AutoDock suiteNature Protocols, 2016
- ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SBJournal of Chemical Theory and Computation, 2015
- Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural DatabaseJournal of Chemical Information and Modeling, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- DrugBank: a comprehensive resource for in silico drug discovery and explorationNucleic Acids Research, 2006
- H++: a server for estimating pKas and adding missing hydrogens to macromoleculesNucleic Acids Research, 2005
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP modelThe Journal of Physical Chemistry, 1993